Table 2.
Demographic data on rituximab recipients and nonrecipients
| Parameter | Proportion (%) |
P valuea | |
|---|---|---|---|
| Rituximab (n = 18) | No rituximab (n = 99) | ||
| Patient demographic characteristic | |||
| Age (median/range) years | 65 (29–78) | 65 (21–81) | |
| Age >60 | 61 | 63 | 1.00 |
| Female | 56 | 49 | .799 |
| ECOG PS >1 | 22 | 34 | .416 |
| Elevated serum LDH | 17 | 45 | .110 |
| Deep lesions | 72 | 55 | .207 |
| Multiple lesions (>1) | 50 | 50 | 1.00 |
| CSF cytology positive | 25 | 13 | .593 |
| Diagnosis after 2004 | 94 | 41 | <.0001 |
| Treatment demographic characteristic | |||
| Cytarabine | 47 | 27 | .150 |
| Radiotherapy | 28 | 37 | .441 |
| Intrathecal methotrexate | 6 | 36 | .011 |
aP value of the 2-tailed Fisher's exact test for difference between rituximab recipients and nonrecipients.